HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elimination of the antimicrobial action of the organoarsenical cancer therapeutic, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, before finished product sterility testing.

AbstractOBJECTIVES:
Arsenical compounds have been used therapeutically for over 2000 years finding particular relevance as antimicrobials. After being replaced by more selective and consequently less toxic antibiotics in the last century, arsenicals have recently made a resurgence as anticancer drugs (specifically arsenic trioxide and its derivatives). Arsenical parenteral formulations require post-manufacture sterility testing; however, their intrinsic antimicrobial activity must be neutralised before testing to eliminate the possibility of false (no-growth) test results.
METHODS:
A range of thiol-containing compounds was screened to establish a suitable deactivation agent for the novel organoarsenical compound, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid (GSAO). Dimercatopropanol (DMP) was found to successful deactivate GSAO and was validated according to pharmacopoeial sterility test guidelines (specifically the method suitability test/sterility validation test).
KEY FINDINGS:
DMP is an effective way of deactivating GSAO before sterility testing and can be used for pharmacopoeial sterility tests. Our results affirm previous research highlighting the sensitivity of Staphylococcus aureus to arsenical compounds
CONCLUSIONS:
A method of deactivating the arsenical drug GSAO before the post-manufacture sterility test was established and validated. DMP is a commonly used chelator/deactivation agent so this work may have implications for other inorganic therapeutic agents.
AuthorsLindsay J Dick, Andrew Gray, Asha Ram, Aileen Hume, Caroline Parris, Philip J Hogg, Moira A Elliott, Steven J Ford, Gavin W Halbert
JournalThe Journal of pharmacy and pharmacology (J Pharm Pharmacol) Vol. 65 Issue 11 Pg. 1664-9 (Nov 2013) ISSN: 2042-7158 [Electronic] England
PMID24102542 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Validation Study)
Copyright© 2013 Royal Pharmaceutical Society.
Chemical References
  • Anti-Infective Agents
  • Antineoplastic Agents
  • Arsenicals
  • Chelating Agents
  • Sulfhydryl Compounds
  • phenylarsonous acid
Topics
  • Anti-Infective Agents (pharmacology)
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Arsenicals (pharmacology, therapeutic use)
  • Chelating Agents (pharmacology)
  • Infusions, Parenteral
  • Neoplasms (drug therapy)
  • Staphylococcus aureus (drug effects)
  • Sulfhydryl Compounds (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: